Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases.
Riccardo PapaValentina NatoliRoberta CaorsiFrancesca MinoiaMarco GattornoAngelo RavelliPublished in: Pediatric rheumatology online journal (2020)
Our report indicates that canakinumab may be efficacious in the management of hyperferritinemic syndromes, including MAS.
Keyphrases